← All cohorts · Chikungunya virus cohorts

TELECHIK cohort (Réunion chikungunya)

source record (JSON) · schema v2.0.0 · CC BY 4.0

Design notes & limitations. Population-based cohort with a seronegative comparator group (582 CHIK- vs 512 CHIK+), interviewed on average 2 years after infection (range 15-34 months, median 23.7). One of the few post-infectious cohorts with a true unexposed control drawn from the same population, allowing attributable-fraction estimation (~60% of polyarthralgia attributable to CHIKV). Ascertainment was retrospective/serological, so acute-phase data are absent.

Identity & trigger

Cohort id
telechik-reunion
Aliases
TELECHIK survey, SEROCHIK/TELECHIK
Outbreak / event
Réunion chikungunya outbreak 2005-06
Pathogen
Chikungunya virus (Virus)
Exposure ascertainment
serology

Design

Design
Retrospective cohort
Denominator defined
Yes
Denominator method
Random population sample drawn from the SEROCHIK population-based serosurvey on Réunion island; participants classified by CHIKV serostatus (IgG).
Recruitment
population registry
Time zero
Acute chikungunya infection during the 2005-06 Réunion outbreak (serologically ascertained retrospectively) (quarter)
Control group
Unexposed (unmatched)

Size & attrition

Enrolled
1094
Analysed / enrolled
1094/1094 (100%)
Max follow-up (months)
34

Biospecimens

Specimens
Yes
Types
serum
Acute-phase specimens
No
Biobank
Unknown
External access
Unknown

Observations (4)

Symptoms

43% Proportion

Measure
Arthralgia / rheumatic musculoskeletal pain sym:arthralgia
As worded
“musculoskeletal pain reported ~2 years after infection (43% in CHIKV-positive vs 17% in CHIKV-negative)”
Population
whole cohort · denominator Assessed at timepoint · N=n=512
Timing
24 mo (12-24 mo) · ref Not reported
Method
Unclear · Structured symptom questionnaire (author-defined)
Comparator
Unexposed (unmatched): 17%
Comparability signature
f4904c7ad7 — measure sym:arthralgia · Unclear · ref Not reported · denom Assessed at timepoint · 12-24 mo · Proportion
Provenance
Results (musculoskeletal pain 43% in CHIK+ vs 17% in CHIK-) · Manual · verified OSMF research-tracker (web-verified against source) on 2026-07-20

29.9% Proportion

Measure
Arthralgia / rheumatic musculoskeletal pain sym:arthralgia
As worded
“long-lasting rheumatic musculoskeletal pain”
Population
whole cohort · denominator Assessed at timepoint · N=n=512
Timing
24 mo (12-24 mo) · ref Since infection
Method
Structured checklist · Structured symptom questionnaire (author-defined)
Comparator
Seronegative contacts: 8.9%
Comparability signature
1ba65d5eec — measure sym:arthralgia · Structured checklist · ref Since infection · denom Assessed at timepoint · 12-24 mo · Proportion
Provenance
Weighted prevalence, CHIKV+ vs CHIKV- (LRMSP 29.9% vs 8.9%) · Manual · verified OSMF research-tracker (web-verified against source) on 2026-07-20

34.3% Proportion

Measure
Fatigue sym:fatigue
As worded
“idiopathic chronic fatigue”
Population
whole cohort · denominator Assessed at timepoint · N=n=512
Timing
24 mo (12-24 mo) · ref Since infection
Method
Structured checklist · Structured symptom questionnaire (author-defined)
Comparator
Seronegative contacts: 12.7%
Comparability signature
9a23fbcd5e — measure sym:fatigue · Structured checklist · ref Since infection · denom Assessed at timepoint · 12-24 mo · Proportion
Provenance
Weighted prevalence, CHIKV+ vs CHIKV- (idiopathic chronic fatigue 34.3% vs 12.7%) · Manual · verified OSMF research-tracker (web-verified against source) on 2026-07-20

Case definitions

21.5% Proportion

Measure
CFS-like illness case-def:cfs-like
As worded
“chronic fatigue syndrome-like illness”
Population
whole cohort · denominator Assessed at timepoint · N=n=512
Timing
24 mo (12-24 mo) · ref Since infection
Method
Structured checklist · Structured symptom questionnaire (author-defined)
Comparator
Seronegative contacts: 6.7%
Comparability signature
cba91d3ab5 — measure case-def:cfs-like · Structured checklist · ref Since infection · denom Assessed at timepoint · 12-24 mo · Proportion
Provenance
Weighted prevalence, CHIKV+ vs CHIKV- (CFS-like illness 21.5% vs 6.7%) · Manual · verified OSMF research-tracker (web-verified against source) on 2026-07-20

Publications

Provenance & verification

Registration
n/r
Funders
INSERM, French Ministry of Health
Related cohorts
schilte-2013-chikungunya-reunion (Sibling analysis), marimoutou-2012-gendarmes (Sibling analysis)
Symptom-inventory scope
Targeted panel
Last verified
2026-07-20 — OSMF research-tracker (web-verified against source)